Rockwell Medical (NASDAQ:RMTI) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Rockwell Medical (NASDAQ:RMTI) in a research note published on Monday morning,Benzinga reports. The firm currently has a $7.00 price objective on the stock.

Other analysts also recently issued reports about the company. RODMAN&RENSHAW upgraded Rockwell Medical to a “strong-buy” rating in a report on Thursday, November 14th. Rodman & Renshaw assumed coverage on Rockwell Medical in a research note on Thursday, November 14th. They set a “buy” rating and a $5.00 price target for the company. Finally, StockNews.com lowered Rockwell Medical from a “buy” rating to a “hold” rating in a research note on Friday.

Rockwell Medical Price Performance

Rockwell Medical stock opened at $2.11 on Monday. Rockwell Medical has a 1 year low of $1.16 and a 1 year high of $5.15. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.00 and a current ratio of 2.41. The firm has a 50 day moving average price of $2.86 and a 200 day moving average price of $2.71. The company has a market cap of $68.19 million, a price-to-earnings ratio of -42.20 and a beta of 1.38.

Institutional Trading of Rockwell Medical

A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its stake in shares of Rockwell Medical by 877.1% during the second quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock worth $181,000 after purchasing an additional 92,189 shares in the last quarter. Armistice Capital LLC raised its holdings in shares of Rockwell Medical by 22.5% during the 2nd quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock valued at $5,670,000 after buying an additional 592,000 shares during the period. Beacon Financial Advisory LLC acquired a new position in Rockwell Medical during the 3rd quarter worth approximately $98,000. Concurrent Investment Advisors LLC purchased a new position in Rockwell Medical in the 3rd quarter worth approximately $40,000. Finally, Verus Capital Partners LLC acquired a new stake in Rockwell Medical in the third quarter valued at approximately $51,000. 23.31% of the stock is owned by hedge funds and other institutional investors.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.